Tratamiento del carcinoma de estómago avanzado con adriamicina v 5-fluorouracilo. / [Treatment of advanced stomach carcinoma with adriamycin and 5-fluorouracil]
Pérez, J E; Macchiavelli, M; Leone, B A; Romero, A; Rabinovich, M G; Arévalo, E; Strauss, E.
Acta gastroenterol. latinoam
; 14(1): 63-72, 1984.
Artículo
en Español
| BINACIS | ID: bin-49674
Advanced gastric carcinoma is one of the digestive tract sites which best responds to chemotherapy. Single drug therapy offers an objective regression between 0.30
(Table I). Combined chemotherapy is considered to be more effective, results varying from 6.55
(Table II). Since March 1979 till May 1983, we initiated a cooperative protocol between the hospitals J. M. Penna and L. Lucero of Bahía Blanca and the Regional Hospital of Neuguén, for the treatment of advanced gastric carcinoma, associating 5-fluorouracil (5FU) and adriamycin (ADM). Characteristics of the 20 evaluated patients are shown in Table III. Objective regressions represented 40
(8/20 patients), with a median duration of 8, 5 months (Table IV). The mean survival rate of responders was 11.5 months and of non-responders 3,5 months (P +/- 0.005). Table V illustrates the clinical status and response induced by this therapy. Tolerance was acceptable (Table VI). Severe or very severe toxicity reported in other trials after the administration of 5-FU - ADM combined with methyl CCNU or mitomycin C, did not occur. In our study there was no indication to interrupt therapy due to hematologic or non-hematologic side effects. Results indicate that the combination 5-FU - ADM might be promising for this neoplasm and should be further investigates in a larger number of patients in order to establish its real usefulness.
(Table I). Combined chemotherapy is considered to be more effective, results varying from 6.55
(Table II). Since March 1979 till May 1983, we initiated a cooperative protocol between the hospitals J. M. Penna and L. Lucero of Bahía Blanca and the Regional Hospital of Neuguén, for the treatment of advanced gastric carcinoma, associating 5-fluorouracil (5FU) and adriamycin (ADM). Characteristics of the 20 evaluated patients are shown in Table III. Objective regressions represented 40
(8/20 patients), with a median duration of 8, 5 months (Table IV). The mean survival rate of responders was 11.5 months and of non-responders 3,5 months (P +/- 0.005). Table V illustrates the clinical status and response induced by this therapy. Tolerance was acceptable (Table VI). Severe or very severe toxicity reported in other trials after the administration of 5-FU - ADM combined with methyl CCNU or mitomycin C, did not occur. In our study there was no indication to interrupt therapy due to hematologic or non-hematologic side effects. Results indicate that the combination 5-FU - ADM might be promising for this neoplasm and should be further investigates in a larger number of patients in order to establish its real usefulness.
Biblioteca responsable:
AR40.1
Documentos relacionados